The Uptick in AI Use Will Bring Pharma Into the Future Faster

In this PharmaVOICE article, industry experts weigh in on the potential impact of artificial intelligence (AI) in 2020. Rebecca Kush, Ph.D., chief scientific officer at Elligo, gives her perspective, which includes advice to ensure the quality and variety of the underlying data that powers it. She also shares her opinion on where AI would be most valuable: on larger studies, safety or post-marketing studies, and feasibility studies based on real-world data.